来源：市场资讯 （来源：中信证券发布） 2025年12月17日，Park Medi World Limited（以下简称Park Hospitals，NSE:PRKM）成功在印度证券交 易所上市，募集资金约1.02亿美元。中信证券为四家联席账簿管理人之一，是本项目中唯一的非本地投 行。 印度大型私人医院集团 综合多专科医院网络赋能医疗服务 中信证券发挥全球服务优势 助力超额认购完成发行 中信证券发挥全球网络优势，提供国际化综合投行服务。在本项目中，中信证券积极向机构投资者展示 Park Hospitals的成长故事与行业领先地位，基石投资部分认购踊跃，吸引了包括印度本土公募基金、海 外长线机构投资者以及其他本土投资者在内的高质量投资者积极参与。此次IPO中，约84%为新股发 行，约16%为旧股出售，整体需求强劲，主账簿超额认购约8倍。 Park Hospitals （股票代码：NSE:PRKM) Park Hospitals是北印度第二大私人医院集团，提供30多个超专科和专科医疗服务，包括内科、神经科、 泌尿科、胃肠科、普通外科、骨科及肿瘤科等。Park Hospitals由Dr. Ajit Gupta与Dr ...

Core Viewpoint - Zhuozheng Medical is making a third attempt to go public in Hong Kong to avoid risks associated with a redemption agreement expiring at the end of 2026, following two failed IPO attempts in 2024 and 2025 [1][2]. Financial Performance - As of August 31, 2025, Zhuozheng Medical reported a net profit of 0.83 billion RMB, with operating profit reaching 0.13 billion RMB after excluding the impact of the fair value changes of convertible redeemable preferred shares [13]. - The company achieved revenue growth from 6.15 billion RMB for the eight months ending August 31, 2024, to 6.96 billion RMB for the same period in 2025, driven by increased patient visits in various specialties [13]. - Zhuozheng Medical's operating losses narrowed over four years, with figures of -2.51 billion RMB, -2.22 billion RMB, -3.53 billion RMB, and a profit of 0.8 billion RMB in 2024 [10][11]. Debt Situation - Zhuozheng Medical has a high debt burden, with total liabilities reaching 2.325 billion RMB as of August 31, 2025, and an asset-liability ratio exceeding 200% for four consecutive years [5][6]. - The company holds 2.326 billion RMB in convertible redeemable preferred shares, which significantly contribute to its high leverage and liquidity risks [4][8]. - The structure of the debt is concerning, with over 90% of liabilities being current, primarily due to the convertible redeemable preferred shares [6][8]. IPO Strategy - The upcoming IPO is seen as a critical move to convert preferred shares into common equity, thereby alleviating the debt burden and improving the company's financial structure [9]. - The funds raised from the IPO are intended for upgrading existing medical facilities, relocating a facility in Shenzhen, and establishing new locations in Hangzhou and Shanghai [14]. Market Position and Challenges - Zhuozheng Medical is positioned as the third-largest private mid-to-high-end comprehensive medical service provider in China, with a market share of 2.0% as of 2024 [1]. - The average cost per visit for offline medical services is 1,185 RMB, which is significantly higher than public and many private institutions, potentially limiting market expansion due to price sensitivity among patients [15]. - The company aims to transition from a high-end hospital model to a more integrated family healthcare service model, addressing the growing demand for chronic disease management and family healthcare [10].